Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

(2017) Teresa Moran et al.   JOURNAL OF CLINICAL ONCOLOGY

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

(2015) Laura Bonanno et al.   Oncotarget

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

(2014) T. Moran et al.   ANNALS OF ONCOLOGY

The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

(2013) L. Bonanno et al.   ANNALS OF ONCOLOGY

Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2013) Gerold Bepler et al.   JOURNAL OF CLINICAL ONCOLOGY

HERC2 Is an E3 Ligase That Targets BRCA1 for Degradation

(2010) W. Wu et al.   CANCER RESEARCH

HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes

(2009) Simon Bekker-Jensen et al.   NATURE CELL BIOLOGY

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

(2009) Rafael Rosell et al.   PLoS One

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER